STRATEC SE

Earnings Release • Oct 26, 2004

News Details

Ad-hoc | 26 October 2004 11:30

STRATEC: First nine months EPS already exceeds entire previous year’s result

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– STRATEC First nine months EPS already exceeds entire previous year’s result Birkenfeld, October 26, 2004 The Board of Management of STRATEC Biomedical Systems AG, listed in the German Prime Standard and in Gate-M, hereby announces the results for the first nine months of FY 2004, pursuant to Section 15 of the German Securities Trading Law (WpHG). STRATEC increased its earnings to EUR 1.912m (2003: EUR 1.069m). This results in earnings per share (EPS) amounting to EUR 0.58 (2003: EUR 0.32). The diluted earnings per share are EUR 0.57 (2003:EUR 0.32). Sales was increased by 23.2% to EUR 28.022m (2003: EUR 22.739m). The overall performance improved by 21.2% to EUR 29.397m (2003: EUR 24.264m). At the end of the third quarter, STRATEC had 172 employees (2003: 144). Overview of Key Figures pursuant to IFRS (International Financial Reporting Standards): Key figures in 000s 01.01.-09.30.2004 01.01.-09.30.2003 Change Sales 28,022 22,739 + 23.2% Overall performance 29,397 24,264 + 21.2% EBITDA 3,958 2,602 + 52.1% EBIT 3,246 1,946 + 66.8% EBT 3,048 1,746 + 74.6% Net income for the period 1,912 1,069 + 78.9% end of ad-hoc-announcement (c)DGAP 26.10.2004 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: By means of logistical measures undertaken in the procurement and production divisions, it has largely been possible to neutralize the effects of the cycles traditionally observed within the course of business of a given financial year. Significant events arising subsequent to the interim reporting date (September 30, 2004) pursuant to IAS 34.16 (h) and prior to the press date of this interim report: the achievement of certain development goals has allowed to transfer prepayments of EUR 2.9m into turnover. Accordingly work in progress (services) as shown in the inventory (valued according to IAS 38) decreased by the same amount. Although this procedure is not affecting income, it has a bearing on the relation of overall performance to sales. The more extensive interim report can be downloaded from our homepage from around 3 p.m. on November 10, 2004. About STRATEC Biomedical Systems AG STRATEC (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the trading segment Gate-M of the Stuttgart Stock Exchange and on other exchanges. Further information can be obtained from: STRATEC Biomedical Systems AG Investor Relations André Loy Gewerbestrasse 37 75217 Birkenfeld Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 E-Mail: ir@stratec-biomedical.de ——————————————————————————– WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart; Freiverkehr in Berlin-Bremen, Düsseldorf und München 261130 Okt 04